206 related articles for article (PubMed ID: 35671105)
1. Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barré syndrome mouse model.
McGonigal R; Campbell CI; Barrie JA; Yao D; Cunningham ME; Crawford CL; Rinaldi S; Rowan EG; Willison HJ
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35671105
[TBL] [Abstract][Full Text] [Related]
2. Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model.
Campbell CI; McGonigal R; Barrie JA; Delaere J; Bracke L; Cunningham ME; Yao D; Delahaye T; Van de Walle I; Willison HJ
Brain Commun; 2022; 4(6):fcac306. PubMed ID: 36523267
[TBL] [Abstract][Full Text] [Related]
3. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy.
McGonigal R; Cunningham ME; Yao D; Barrie JA; Sankaranarayanan S; Fewou SN; Furukawa K; Yednock TA; Willison HJ
Acta Neuropathol Commun; 2016 Mar; 4():23. PubMed ID: 26936605
[TBL] [Abstract][Full Text] [Related]
4. Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain-Barré syndrome.
Cunningham ME; McGonigal R; Barrie JA; Campbell CI; Yao D; Willison HJ
J Peripher Nerv Syst; 2023 Mar; 28(1):17-31. PubMed ID: 36710500
[TBL] [Abstract][Full Text] [Related]
5. Real time imaging of intra-axonal calcium flux in an explant mouse model of axonal Guillain-Barré syndrome.
Cunningham ME; McGonigal R; Barrie JA; Yao D; Willison HJ
Exp Neurol; 2022 Sep; 355():114127. PubMed ID: 35640716
[TBL] [Abstract][Full Text] [Related]
6. The immunobiology of Guillain-Barré syndromes.
Willison HJ
J Peripher Nerv Syst; 2005 Jun; 10(2):94-112. PubMed ID: 15958123
[TBL] [Abstract][Full Text] [Related]
7. Perisynaptic Schwann cells phagocytose nerve terminal debris in a mouse model of Guillain-Barré syndrome.
Cunningham ME; Meehan GR; Robinson S; Yao D; McGonigal R; Willison HJ
J Peripher Nerv Syst; 2020 Jun; 25(2):143-151. PubMed ID: 32250537
[TBL] [Abstract][Full Text] [Related]
8. Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.
Fewou SN; Rupp A; Nickolay LE; Carrick K; Greenshields KN; Pediani J; Plomp JJ; Willison HJ
J Clin Invest; 2012 Mar; 122(3):1037-51. PubMed ID: 22307327
[TBL] [Abstract][Full Text] [Related]
9. [Case of pure motor Guillain-Barré syndrome with motor conduction block and anti-GM1/GalNAc-GD1a antibody].
Ogawa G; Kaida K; Shiozaki Y; Araki M; Kimura F; Kamakura K
Rinsho Shinkeigaku; 2009 Aug; 49(8):488-92. PubMed ID: 19827599
[TBL] [Abstract][Full Text] [Related]
10. [Antibodies to ganglioside GM1 and Campylobacter jejuni in patients with Guillain-Barré syndrome].
Basta I; Suturkova L; Vujić A; Aleksić S; Poceva A; Paskoska A; Milenikova K; Trikić R; Apostolski S
Srp Arh Celok Lek; 2005; 133(3-4):123-8. PubMed ID: 16206698
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy.
Goodfellow JA; Bowes T; Sheikh K; Odaka M; Halstead SK; Humphreys PD; Wagner ER; Yuki N; Furukawa K; Furukawa K; Plomp JJ; Willison HJ
J Neurosci; 2005 Feb; 25(7):1620-8. PubMed ID: 15716397
[TBL] [Abstract][Full Text] [Related]
12. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome.
Hiraga A; Kuwabara S; Ogawara K; Misawa S; Kanesaka T; Koga M; Yuki N; Hattori T; Mori M
Neurology; 2005 Mar; 64(5):856-60. PubMed ID: 15753422
[TBL] [Abstract][Full Text] [Related]
13. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.
Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S
Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484
[TBL] [Abstract][Full Text] [Related]
14. Ganglioside mimicry as a cause of Guillain-Barré syndrome.
Yuki N; Odaka M
Curr Opin Neurol; 2005 Oct; 18(5):557-61. PubMed ID: 16155440
[TBL] [Abstract][Full Text] [Related]
15. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies.
Uncini A; Susuki K; Yuki N
Clin Neurophysiol; 2013 Oct; 124(10):1928-34. PubMed ID: 23639374
[TBL] [Abstract][Full Text] [Related]
16. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
[TBL] [Abstract][Full Text] [Related]
17. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics.
St Charles JL; Bell JA; Gadsden BJ; Malik A; Cooke H; Van de Grift LK; Kim HY; Smith EJ; Mansfield LS
J Autoimmun; 2017 Feb; 77():11-38. PubMed ID: 27939129
[TBL] [Abstract][Full Text] [Related]
18. Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever.
Prado MB; Narito KM; Adiao KJB
J Neuroimmunol; 2021 Jun; 355():577572. PubMed ID: 33862418
[TBL] [Abstract][Full Text] [Related]
19. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies.
Susuki K; Yuki N; Schafer DP; Hirata K; Zhang G; Funakoshi K; Rasband MN
Exp Neurol; 2012 Jan; 233(1):534-42. PubMed ID: 22178332
[TBL] [Abstract][Full Text] [Related]
20. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
